Infectious Vaccines Partnering Terms and Agreements

ReportLinker Find Industry reports, Company profilesand Market Statistics

>> Get this Report Now by email!

Infectious Vaccines Partnering Terms and Agreements

Published on December 2013

Report Summary

The Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and analysis of how and why

companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a

right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative

R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in

terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the

payments clauses, the devil is in the detail in terms of how payments are triggered ' contract documents provide this insight where

press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2007, including

financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as

disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities

Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important

issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company'

What exclusivity is granted'

What are the precise rights granted or optioned'

What is the payment structure for the deal'

How are sales and payments audited'

What is the deal term'

How are the key terms of the agreement defined'

How are IPRs handled and owned'

Who is responsible for commercialization'

Who is responsible for development, supply, and manufacture'

How is confidentiality and publication managed'

How are disputes to be resolved'

Under what conditions can the deal be terminated'

What happens when there is a change of ownership'

What sublicensing and subcontracting provisions have been agreed'

Which boilerplate clauses does the company insist upon'

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type'

Which jurisdiction does the company insist upon for agreement law'

Infectious Vaccines Partnering Terms and Agreements (From Issuu) Page 1/23

http://www.reportlinker.com?utm_campaign=plp&utm_source=issuu&utm_medium=referral



http://www.reportlinker.com/p01921535/Infectious-Vaccines-Partnering-Terms-and-Agreements.html#utm_campaign=plp&utm_source=issuu&utm_medium=referral




The initial chapters of this report provide an orientation of infectious vaccines dealmaking and business activities. Chapter 1 provides

an introduction to the report, whilst chapter 2 provides an overview of the trends in infectious vaccines dealmaking since 2007,

including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading infectious vaccines deals since 2007. Deals are listed by headline value. Where the deal

has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies for which deals are available, with a brief summary

followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where

available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each

contract document on demand.

Chapter 5 provides a comprehensive listing of the big biotech companies for which deals are available, with a brief summary followed

by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where

available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each

contract document on demand.

Chapter 6 provides a comprehensive and detailed review of infectious vaccines partnering deals signed and announced since

January 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of

development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology

type focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document,

providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in infectious vaccines partnering and

dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development

and commercialization of infectious vaccines technologies and products..

Report scope

Infectious Vaccines Partnering Agreements is intended to provide the reader with an in-depth understanding and access to infectious

vaccines trends and structure of deals entered into by leading companies worldwide.

Infectious Vaccines Partnering Agreements includes:

Trends in infectious vaccines dealmaking in the biopharma industry since 2007

Analysis of infectious vaccines deal structure

Access to headline, upfront, milestone and royalty data

Access to over 700 infectious vaccines deal records

The leading infectious vaccines deals by value since 2007

Includes adjuvant deals and alliances since 2007

In Infectious Vaccines Partnering Agreements, the available deals are listed by:

Company A-Z

Headline value









Stage of development at signing

Deal component type

Specific infectives therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy

access to each contract document on demand.

The Infectious Vaccines Partnering Agreements report provides comprehensive access to available deals and contract documents for

over 700 infectious vaccines deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned'

What is actually granted by the agreement to the partner company'

What exclusivity is granted'

What is the payment structure for the deal'

How aresalesand payments audited'

What is the deal term'

How are the key terms of the agreement defined'

How are IPRs handled and owned'

Who is responsible for commercialization'

Who is responsible for development, supply, and manufacture'

How is confidentiality and publication managed'

How are disputes to be resolved'

Under what conditions can the deal be terminated'

What happens when there is a change of ownership'

What sublicensing and subcontracting provisions have been agreed'

Which boilerplate clauses does the company insist upon'

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type'

Which jurisdiction does the company insist upon for agreement law'

Key benefits

Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

' In-depth understanding of infectious vaccines deal trends since 2007

' Access infectious vaccines deal headline, upfront, milestone and royalty data

' Research hundreds of actual contracts between infectious vaccines partner companies

' Comprehensive access to over 700 links to actual infectious vaccines deals entered into by the world's biopharma companies

' Indepth review of infectious vaccines deals entered into by the leading fifty bigpharma companies

' Benchmark the key deal terms companies have agreed in previous deals

' Identify key terms under which companies partner infectious vaccines opportunities

' Uncover companies actively partnering infectives vaccine opportunities









Table of Content

Executive Summary

Chapter 1 ' Introduction

Chapter 2 ' Trends in Infectious Vaccines dealmaking

2.1. Introduction

2.2. Infectious Vaccines partnering over the years

2.3. Big pharma Infectious Vaccines dealmaking activity

2.4. Big biotech Infectious Vaccines dealmaking activity

2.4. Most active in Infectious Vaccines partnering

2.5. Infectious Vaccines partnering by deal type

2.6. Infectious Vaccines partnering by stage of development

2.7. Infectious Vaccines partnering by infectives indication

2.8. Infectious Vaccines partnering by vaccine and adjuvant indication

2.9. Disclosed deal terms for Infectious Vaccines partnering

2.9.1 Infectious Vaccines partnering headline values

2.9.2 Infectious Vaccines deal upfront payments

2.9.3 Infectious Vaccines deal milestone payments

2.9.4 Infectious Vaccines royalty rates

2.10. The anatomy of Infectious Vaccines partnering

2.10. The anatomy of a Infectious Vaccines deal

2.10.a. Case study 1: Gilead Sciences, GlobeImmune- Oct 24 2011

2.10.b. Case study 2: Astellas, Vical: July 14, 2011

Chapter 3 ' Leading Infectious Vaccines deals

3.1. Introduction

3.2. Top Infectious Vaccines deals by value

Chapter 4 ' Bigpharma Infectious Vaccines deals

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Big pharma Infectious Vaccines partnering company profiles

Abbott

Astellas

AstraZeneca

Baxter International

Bayer

CSL

Daiichi Sankyo

Eisai

Gilead Sciences









GlaxoSmithKline

Johnson & Johnson

Kyowa Hakko Kirin

Merck & Co

Mitsubishi Tanabe

Novartis

Pfizer

Roche

Sanofi

Shionogi

Takeda

Chapter 5 ' Big biotech Infectious Vaccines deals

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech Infectious Vaccines partnering company profiles

Bavarian Nordic

Cangene

Emergent BioSolutions

Chapter 6 ' Infectious Vaccines dealmaking directory

6.1. Introduction

6.2. Company A-Z

3M

A*STAR Agency for Science, Technology and Research

A*STAR Bioprocessing Technology Institute

A*STAR Singapore Immunology Network

Aaron Diamond AIDS Research Center

Abbott Laboratories

Aberystwyth University

Absynth Biologics

Academia Sinica

Acambis

Accelovance

ACE BioSciences

Achaogen

ADImmune

Aduro BioTech

Advanced BioNutrition

Advanced BioScience Laboratories

Advanced Immunization Technologies (ADITEC)

Advaxis

Aeras Global TB Vaccine Foundation

AFFiRiS

Agenus Bio

Agilent Technologies









Ajanta Pharma

Akorn

Akshaya Bio

Albany Medical College

Albert Einstein College of Medicine

Aldevron

Alexis Biotech

Algonomics

ALK-Abello

Allied Healthcare Group

Alnylam Pharmaceuticals

Alphavax

Althea Technologies

AltraVax

American Type Culture Collection (ATCC)

AmVac

Amyris Biotechnologies

AnC Bio

AnGes MG

Antelope Valley Biologics

Antigen Discovery

Antigen Express

Antigenics

Antitope

Apogee Biotechnology

Apotex

Archimedes Development

Archimedes Pharma

Arecor

Argos Therapeutics

Ariad Pharmaceuticals

AriaVax

Arizona State University

Ark Therapeutics

Artepharm Co

Artepharm Global

Artes Biotechnology

Astellas Pharma

Astellas Pharma US

AstraZeneca

Astrogenetix

Atreca

Australian Centre for Vaccine Development

Australian National University

Avac

AVANT Immunotherapeutics

Avecia Biologics

AVI Pharma









Avid Bioservices

Avimex

Barr Pharmaceuticals

Battelle

Bavarian Nordic

Baxter International

Bayer

Beijing Health Bureau

Beijing Tiantan Biological Products

Beth Israel Deaconess Medical Center

Biken

Bill and Melinda Gates Foundation

BinnoPharm

Bio-Manguinhos

BioAlliance Pharma

BioCryst Pharmaceuticals

BioDiem

Biofactura

Bioject Medical Technologies

Biolik Biopharmaceutical

Biological E

Biomedical Advanced Research and Development Authority

BiondVax

Bioniche Life Sciences

Bionor Pharma

BioPharm Services

BioReliance

Biota

Biotechnology and Biological Sciences Research Council (BBSRC)

BioVeris

BioVest

Birmex

Boryung Pharmaceutical

Brigham Young University

Butantan Institute

Cadila Pharmaceuticals

Cambridge BioStability

Cangene

Capsulation NanoScience

Carrington Laboratories

Case Western Reserve University

Catherex

Catholic University of America

Celldex Therapeutics

Cellectis Bioresearch

Centegen

Centers for Disease Control and Prevention

Centre National de Recherche et de Formation sur le Paludisme









Centro de Investigacion y Asistencia Tecnologica y Diseno del Estado de Jalisco

Centrovet

Centrovet Laboratories

Ceva Sante Animale

Cevec Pharmaceuticals

Changchun BCHT Biotechnology

ChemRar High-Tech Center

Chengdu Institute of Biological Products

Cheyney University

China Centre for Disease Control

China National Biotech Group (CNBG)

Chinese Center for Disease Control and Prevention

Chinese Federal Government

Chongqing Zhifei Biological Products

ChronTech Pharma

Chumakov Institute of Poliomyelitis and Viral Encephalitides

ClinTec International

Cobra Biologics

Coley Pharmaceutical Group

Colorado Institute for Drug, Device and Diagnostic Development

Compass Biotechnologies

Corgenix Medical

CPL Biologicals

Critical Path Institute (C-Path)

Crossbeta Biosciences

Crucell

Crucible International Biotechnologies

CSIRO

CSL

CSL Biotherapies

CureVac

Cytodyn

CytoGenix

Cytos Biotechnology

Cyvax

Daiichi Pharmaceutical

Daiichi Sankyo

Dalton Pharma Services

Dana-Farber Cancer Institute

Danish Defence

Dartmouth College

DBV Technologies

Defence Research and Development Canada

Defense Advanced Research Projects Agency

Defense Threat Reduction Agency

Defyrus

Delphi Genetics

Delsite









Department of Defense

Department of Health and Human Services

Department of Homeland Security

Diagnostic Hybrids

DOR BioPharma

Drexel University

DRI Capital

Drugs for Neglected Diseases Initiative

Duke-NUS Graduate Medical School Singapore

Duke University

Duke University Medical Center

Dynavax Technologies

DynPort Vaccine Company

Eden Biodesign

Eisai

Elanco

Emcure Pharmaceuticals

EMD Millipore

Emergent BioSolutions

Emergent Product Development

Emory University

Encorium Group

Endobiologics

EnWave

Epic Bio

EpiCept

Epitopix

Erasmus University Medical Center

Esteve

European Commission

European Union

European Vaccine Initiative

Evolutec

Evolva

Exploit Technologies

ExpreS2ion Biotechnologies

Fabentech

Fina Biosolutions

FIT Biotech

FluGen

Food and Drug Administration (FDA)

Formatech

Fort Dodge Animal Health

Fourth Military Medical University

Fraunhofer USA

Fraunhofer USA Center for Molecular Biotechnology

French National Institute for Agricultural Research

French National Research Agency









Fusion IP

G-Con

Gador

Gamma Vaccines

GE Healthcare

Geneart

Generex Biotechnology

GeneThera

Genetic Immunity

Genocea Biosciences

GenomIdea

GenPhar

GenVec

GeoVax

German Cancer Research Center

Gilead Sciences

GlaxoSmithKline

GlaxoSmithKline Biologicals

Glide

Global Green

GlobeImmune

GlycoMimetics

Glycosensors and Diagnostics

GlycoVaxyn

GNI

Goodwin Biotechnology

Government of Canada

Government of China

Government of India

Government of Japan

Government of United Kingdom

Green Cross

Harbin Pharmaceutical Group

Harrisvaccines

Harvard Medical School

Harvard University

Hawaii Biotech

Health Protection Agency (HPA)

Heat Biologics

Helmholtz Centre for Infection Research

HemispheRx Biopharma

Henderson Morley

Henry Schein

HIV Vaccine Trials Network (HVTN)

Hollister-Stier Labs

Hunan Biopharmaceutical

IBio

IBioPharma









Ichor Medical Systems

Icon Genetics

ID Biomedical

IHI

IHI Plant Engineering Corporation

Imaxio

ImmBio

Immune Design

ImmuneRegen BioSciences

Immunomedics

Immunovaccine

ImmunoVaccine Technologies

Imperial Innovations

Imugene

In Cell Art

Inclinix

Infectious Disease Research Institute (IDRI)

Inovio Biomedical

Inovio Pharmaceuticals

Inserm

Institut Pasteur

Institute for Medical Microbiology, Immunology and Hygiene (IMMIH)

Institute for OneWorld Health

Integrated Biopharma

Integrated BioTherapeutics

Intercell

International AIDS Vaccine Initiative

International Center for Genetic Engineering and Biotechnology

International Medica Foundation

International Vaccine Institute (IVI)

Intervet

Inviragen

InVitria

Iomai

Ippox Foundation

IQ Products

IQur

IrsiCaixa AIDS Research Institute

Isconova

Istituto Superiore di Sanita

Italian Government

Janssen Pharmaceutica NV

Janssen Pharmaceutical

Jantibody Therapeutics

Japan Government

Jenner Institute

Jiangsu Walvax

Johns Hopkins University









Johnson & Johnson

JSC Binnopharm

Juvaris BioTherapeutics

Kaketsuken

Karolinska Institute

Kirin Pharma

Kitasato Daiichi Sankyo Vaccine

Kitasato Institute

Kyoto Biken

Kyowa Hakko Kirin

La Jolla Institute for Allergy & Immunology

Lallemand Pharma Europe

Lebanese-Canadian Hospital

Leiden University

Leidos Holdings

Lentigen

LG Life Sciences

LigoCyte Pharmaceuticals

Lipotek

Lipoxen

Liquidia Technologies

Lohmann Animal Health

Lonza

Lovelace Respiratory Research Institute

Lucigen

Mahidol University

Maryland Technology Development Corporation

Massachusetts Biologic Laboratories

Massachusetts General Hospital

MassBiologics

Max-Planck

Max Planck Institute for Dynamics of Complex Technical Systems

Maxcyte

Maxygen

Mayo Clinic

McMaster University

Medicago

Medicine in Need

Medicines for Malaria Venture

MediGene

MedImmune

Medison Pharma

Mellow Hope Bio Chem

Merck and Co

Merial

Meridian Bioscience

Meridian Life Science

Merix Bioscience









Metabolon

Microbix Biosystems

Military HIV Research Program (MHRP)

Ministry of Defence

Ministry of Health of Brazil

Mitsubishi Tanabe Pharma

Mologen

Monash University

MonoSol Rx

Mount Sinai School of Medicine

MPI Research

MSD Wellcome Trust Hilleman Laboratories

Mucosis

Mymetics

Nabi Biopharmaceuticals

NanoBio

Nanotherapeutics

NanoViricides

Narvac

NASA

NasVax

National Cancer Institute

National Health and Medical Research Council

National Healthcare Services (NHS)

National Institute of Allergy and Infectious Diseases

National Institute of Infectious Diseases

National Institute of Nanotechnology

National Institute on Drug Abuse (NIDA)

National Institutes of Health

National Microbiology Laboratory

National Research Council Canada

National University of Singapore

Naval Medical Research Center

Navy Medical Research Centre

Netherlands Vaccine Institute

Neugenesis

New York Medical College

Niigata TLO/NBRP/KUTLO-NITT

Ninebio

NineSigma

Nobilon

Noguchi Memorial Institute for Medical Research

North West Fund

Novartis

Novartis Vaccines

Novation

Novavax

Novozymes









Numerate

Nuron Biotech

NYU Langone Medical Center

Omnia Biologics

Omnivest

Opal Therapeutics

OPKO Health

Opsona Therapeutics

Ortho-McNeil-Janssen Pharmaceuticals

Ortho-McNeil

OSEO

Oswaldo Cruz Foundation

Oswaldo Cruz Foundation (Fiocruz)

Oxford- Emergent Tuberculosis Consortium

Oxford BioMedica

PacificGMP

Paladin Labs

Pan-Provincial Vaccine Enterprise

Pan American Health Organization

Paragon Bioservices

Parenteral Biotech

PATH (Appropriate Technology in Health)

PATH Malaria Vaccine Initiative

PaxVax

PECET

Pediatric Dengue Vaccine Initiative

Pennsylvania Department of Health

Pepscan Therapeutics

PepTcell

Peptimmune

PeptiVir

Pevion

Pfenex

Pfizer

Pfizer Animal Health

PharmaJet

Pharmaq

PharmAthene

Pharmexa

Pharmsynthez

Philip Morris Products

Ploughshare Innovations

PPD

Preclin Biosystems

Presido Pharmaceuticals

Prevtec microbia

ProBioGen

Profectus Biosciences









Prokarium

Protein Potential

Protein Sciences

Protherics

PsiOxus Therapeutics

Public Health Agency of Canada

Purdue Research Foundation

Qiagen

Radboud University Nijmegen Medical Centre

Ragon Institute

Rapid Micro Biosystems

Ratio

Receptor Logic

Redbiotec

ReGenX Biosciences

Replikun Biotech

Research Council of Norway

Rhapsody Biologics

Riboxx Pharmaceuticals

Roche

Romark Laboratories

ROVI Pharmaceuticals

Sabin Vaccine Institute

SAIC-Frederick

Sanaria

Sanofi-Aventis

Sanofi-Pasteur

Sanofi

Sanofi Pasteur KK

Saskatchewan Research Council

Scancell

Scarab Genomics

Schering-Plough

SciGen

Scripps Research Institute

Seattle Biomed

SEEK

Select Vaccines

Selecta Biosciences

Sentry BioPharma

Sepragen

Serum Institute of India

Shanghai BravoBio

Shanghai Centers for Disease Control and Prevention

Shantha Biotechnics

Shenzhen Neptunus Interlong Bio-Technique

Shionogi

SIGA Technologies









Sinobiomed

Sinovac Beijing

Sinovac Biotech

SK Chemicals

Skystar Biopharmaceutical

Small Business Innovation Research

Soligenix

Sorrento Therapeutics

Southern Research Institute

SRI International

Stabilitech

Statens Serum Institute

Stellar Biotechnologies

Sumagen

Swiss Tropical and Public Health Institute

Symphony Dynamo

Synthetic Genomics Vaccines

Syntiron

Synvolux Therapeutics

Taiwan Cobia

Takeda Pharmaceutical

Talecris Biotherapeutics

TapImmune

Tasly Pharmaceuticals

TB Alliance

TD Vaccines

Technology Strategy Board

TechnoVax

Telormedix

Temasek Life Sciences

Terumo

Tetragenetics

The International AIDS Vaccine Initiative

The Qater Foundation

Tianjin CanSino Biotechnology

TNO Pharma

Top Institute Pharma

Torii Pharmaceutical

Transgene

Trius Therapeutics

Tuberculosis Vaccine Initiative

Tulane University

UK Government

UK HIV Vaccine Consortium

UMN Pharma

Uniformed Services University of the Health Sciences

UniQuest

United Biomedical









United Nations

United Nations Children Fund

United States Agency for International Development

Universidad de los Andes

University of Adelaide

University of Birmingham

University of British Columbia

University of California, Davis

University of California

University of Canberra

University of Chicago

University of Colorado

University of Connecticut

University of Copenhagen

University of Guelph

University of Kansas

University of Maryland

University of Maryland Biotechnology Institute

University of Maryland School of Medicine

University of Maryland Ventures

University of Massachusetts

University of Massachusetts Medical School

University of Medicine and Dentistry of New Jersey

University of Melbourne

University of Miami Miller School of Medicine

University of Michigan

University of Minnesota

University of New Mexico

University of North Carolina

University of Oxford

University of Pennsylvania

University of Pittsburgh

University of Queensland

University of Rochester

University of Rouen

University of Texas

University of Texas at El Paso

University of Texas Medical Branch

University of Utah

University of Washington

University of Wisconsin

US Army

US Army Medical Research Institute of Infectious Diseases

US Government

VABIOTECH

Vaccibody

Vaccine and Gene Therapy Institute of Florida (VGTI-FL)

Vaccine Technologies









Vakzine Projekt Management

Vandalia Research

VaxDesign

Vaxent

VaxGen

Vaxin

VaxInnate

Vet Cure Pharma

VGX Pharmaceuticals

Vibalogics

Vical

Vichem Chemie

Victorian College of Pharmacy

Viral Genetics

Virbac

ViRexx

Virginia Commonwealth University

Virogen

Virosome Biologicals

ViroStatics

VitamFero

Vivaldi Biosciences

Vivalis

Wageningen University

Walter and Eliza Hall Institute

Walter Reed Army Institute of Research

Wellcome Trust

Wistar Institute

Wittycell

World Bank

World Health Organization

Wyeth

Xcellerex

Xiamen University

Xoma

XTL Biopharmaceuticals

Yokohama City University

Ypsomed

Yunnan Walvax Biotech

Zydus Cadila

6.3. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service









Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Litigation

Manufacturing

Manufacturing - OEM

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

6.4. By stage of development

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

Regulatory

6.5. By infectives therapy area

6.5. By vaccine and adjuvant technology area

Vaccines

Adjuvant

Chapter 7 'Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 ' Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements









Recent report titles from CurrentPartnering

Order Form ' Therapy Reports

Table of figures

Figure 1: Infectious Vaccines partnering since 2007

Figure 2: Bigpharma ' top 50 ' Infectious Vaccines deals 2007 to 2013

Figure 3: Big pharma Infectious Vaccines deal frequency ' 2007 to 2013

Figure 4: Big biotech ' top 50 ' Infectious Vaccines deals 2007 to 2013

Figure 5: Big biotech Infectious Vaccines deal frequency ' 2007 to 2013

Figure 6: Active cancer vaccine dealmaking activity' 2007 to 2013

Figure 7: Infectious Vaccines partnering by deal type since 2007

Figure 8: Infectious Vaccines partnering by stage of development since 2007

Figure 9: Infectious Vaccines partnering by infectives target since 2007

Figure 10: Infectious Vaccines partnering by specific technology target since 2007

Figure 11: Infectious Vaccines deals with a headline value ' by stage of development

Figure 12: Infectious Vaccines deal headline value distribution, US$million ' discovery stage

Figure 13: Infectious Vaccines deal deal headline value distribution, US$million ' preclinical stage

Figure 14: Infectious Vaccines deal deal headline value distribution, US$million ' phase I stage

Figure 15: Infectious Vaccines deal headline value distribution, US$million ' phase II stage

Figure 16: Infectious Vaccines deal deal headline value distribution, US$million ' phase III stage

Figure 17: Infectious Vaccines deal deal headline value distribution, US$million ' marketed stage

Figure 18: Infectious Vaccines deal headline value ' median value by stage of development

Figure 19: Infectious Vaccines deals with upfront payment values ' by stage of development

Figure 20: Infectious Vaccines deal upfront payment value distribution, US$million ' discovery stage

Figure 21: Infectious Vaccines deal upfront payment value distribution, US$million ' preclinical stage

Figure 22: Infectious Vaccines deal upfront payment value distribution, US$million ' phase I stage

Figure 23: Infectious Vaccines deal upfront payment value distribution, US$million ' phase II stage

Figure 24: Infectious Vaccines deal upfront payment value distribution, US$million ' phase III stage

Figure 25: Infectious Vaccines deal upfront payment value distribution, US$million ' marketed stage

Figure 26: Cancer vaccine deal upfront payment value ' median value by stage of development

Figure 27: Infectious Vaccines deals with milestone payment ' by stage of development

Figure 28: Infectious Vaccines deal milestone payment value distribution, US$million ' discovery stage

Figure 29: Infectious Vaccines deal milestone payment value distribution, US$million ' preclinical stage

Figure 30: Infectious Vaccines deal milestone payment value distribution, US$million ' phase I stage

Figure 31: Infectious Vaccines deal milestone payment value distribution, US$million ' phase II stage

Figure 32: Infectious Vaccines deal milestone payment value distribution, US$million ' phase III stage

Figure 33: Infectious Vaccines deal milestone payment value distribution, US$million ' marketed stage

Figure 34: Infectious Vaccines deals with royalty rates-by stage of development

Figure 35: Infectious Vaccines deal royalty rate payment value distribution, US$million ' discovery stage

Figure 36: Infectious Vaccines deal royalty rate payment value distribution, US$million ' preclinical stage

Figure 37: Infectious Vaccines deal royalty rate payment value distribution, US$million ' phase I stage

Figure 38: Infectious Vaccines deal royalty rate payment value distribution, US$million ' phase II stage

Figure 39: Infectious Vaccines deal royalty rate payment value distribution, US$million ' phase III stage

Figure 40: Infectious Vaccines deal royalty rate payment value distribution, US$million ' marketed stage

Figure 41: Infectious Vaccines deal royalty rate payment value ' median value by stage of development

Figure 42: Components of the typical Infectious Vaccines deal structure

Figure 43: Top Infectious Vaccines deals by value since 2007









Figure 44: Online partnering resources

Figure 45: Forthcoming partnering events

Figure 46: Deal type definitions








>> Get this Report Now by email!Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require.

Product Formats Please select the product formats and the quantity you require.

Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________

Infectious Vaccines Partnering Terms and Agreements

1 User License--USD 1 995.00 Quantity: _____

CD-ROM--USD 2 495.00 Quantity: _____

2-5 User License--USD 2 995.00 Quantity: _____

Site License--USD 5 995.00 Quantity: _____

Corporate License--USD 9 975.00 Quantity: _____








>> Get this Report Now by email!Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel

RIB : 10278 07314 00020257701 89

BIC : CMCIFR2A

IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at

http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93

Customer signature:







Documents

Infectious Vaccines Partnering Terms and Agreements